Table 1.
Latest TAP thresholds based on ABodyBuilder1 or ABodyBuilder2 models.
| TAP Property | ABodyBuilder1 | ABodyBuilder2 | ||
|---|---|---|---|---|
| Amber Flag Region | Red Flag Region | Amber Flag Region | Red Flag Region | |
| Ltot | 37 to 42 | <37 | 37 to 42 | <37 |
| 55 to 63 | >63 | 55 to 63 | >63 | |
| PSH | 90.88 to 114.61 | <90.88 | 95.58 to 110.11 | <95.58 |
| 174.26 to 219.20 | >219.20 | 168.06 to 201.59 | >201.59 | |
| PPC | 1.27 to 4.21 | >4.21 | 1.32 to 4.22 | >4.22 |
| PNC | 1.93 to 4.36 | >4.36 | 2.00 to 4.42 | >4.42 |
| SFvCSP | −30.00 to −6.00 | <−30.00 | −30.60 to −6.00 | <−30.60 |
Flagging regions across the five TAP developability metrics calculated over the CSTall dataset (See Methods), when therapeutics are modeled by ABodyBuilder1 or by ABodyBuilder2. As ABodyBuilder1 could not find sufficiently homologous templates to produce a model for Basiliximab, Iscalimab, and Netakimab, its statistics are calculated over 661/664 CSTs. Amber and red flag percentiles were set as per Raybould et al. 201919. Ltot Total CDR Length, PSH Patches of Surface Hydrophobicity metric, PPC Patches of Positive Charge metric, PNC Patches of Negative Charge metric, SFvCSP Structural Fv Charge Symmetry Parameter.